ANI Pharmaceuticals, Inc. announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy. U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.